



| NEONATAL MEDICATION GUIDELINE | | | | | |
|--|-------------------------------------|--|--|--|--|
| Pantoprazole | | | | | |
| Scope (Staff): | Nursing, Medical and Pharmacy Staff | | | | |
| Scope (Area): | KEMH NICU, PCH NICU, NETS WA | | | | |
| This document should be read in conjunction with the Disclaimer. | | | | | |

| Quick Links | Q | ui | ck | Li | n | ks |
|--------------------|---|----|----|----|---|----|
|--------------------|---|----|----|----|---|----|

DosePreparation & AdministrationSide Effects & InteractionsMonitoring

Restrictions

Formulary: Restricted

Description

Proton pump inhibitor (PPI)

Presentation

Vial: 40mg powder for reconstitution

Storage

Store at room temperature, below 25°C. Protect from light

Dose

<u>Treatment of gastro-oesophageal reflux disease; including reflux oesophagitis and upper gastrointestinal bleeding</u>

IV:

1 – 2 mg/kg/dose – may be given as a single dose or in 2 divided doses (every 12 hours)

Preparation

IV Injection

Reconstitute powder for injection with 10mL of Sodium Chloride 0.9%

Concentration = 40mg/10mL = 4mg/mL

IV Infusion

Reconstitute powder for injection with 10mL of Sodium Chloride 0.9%

Concentration = 40mg/10mL = 4mg/mL

Take 1mL (4mg) of the reconstituted solution and make up to a final volume of 10mL with a compatible fluid

Concentration = 4mg/10mL = 0.4mg/mL

Administration

IV Injection

Give at a concentration of 4mg/mL over 2 minutes

IV Infusion

Infuse at a concentration of 0.4mg/mL over 15 minutes

Compatible Fluids

Glucose 5%, Glucose 10% (Somac® brand only), Sodium Chloride 0.9%

Side Effects

Common: vomiting, constipation, flushing

Serious: anaemia, hypoxia, contact dermatitis

Interactions

Pantoprazole may decrease the absorption of thyroxine (levothyroxine) – separate doses by 2 hours

Do not mix undiluted pantoprazole with any other drugs

Monitoring

Monitor serum magnesium with long term use

Comments

Change to oral omeprazole as soon as practicable

KEMH stock Pantoprazole Sandoz® which is EDTA-free

Refer to KEMH Neonatal Medication Guideline: Y-Site IV Compatibility in Neonates

References

Australian Medicines Handbook. Pantoprazole. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2021 [cited 2021 Jun 03]. Available from: https://amhonline.amh.net.au/

Society of Hospital Pharmacists of Australia. Pantoprazole. In: Australian Injectable Drugs Handbook [Internet]. [St Leonards, New South Wales]: Health Communication Network; 2021 [cited 2021 Jun 03]. Available from: http://aidh.hcn.com.au

Australasian Neonatal Medicines Formulary. Pantoprazole. In: Australasian Neonatal Medicines Formulary [Internet]. New South Wales: Australasian Neonatal Medicines Formulary; 2021 [cited 2021 Jun 03]. Available from: https://www.anmfonline.org/

Truven Health Analytics. Pantoprazole. In: NeoFax [Internet]. Greenwood Village (CO): Truven Health Analytics; 2021 [cited 2021 Jun 03]. Available from: https://neofax.micromedexsolutions.com

Plover C, Porrello E. Paediatric injectable guidelines 2019 ed. Flemington (Victoria): The Royal Children's Hospital Melbourne; 2019

Takemoto CK, Hodding JH, Kraus DM. Pediatric & neonatal dosage handbook with international trade names index: a universal resource for clinicians treating pediatric and neonatal patients. 27th ed. Hudson (Ohio): Lexicomp; 2020

| Keywords | Pantoprazole, proton pump inhibitor, PPI, GORD, reflux, Somac | | | | | | | | |
|---|---|-------------------|------------|--|--------------|------------|--|--|--|
| Document Owner: | Head of Department - Neonatology | | | | | | | | |
| Author/ Reviewer | KEMH & PCH Pharmacy/Neonatology Directorate | | | | | | | | |
| Version Info: | 4.0 | | | | | | | | |
| Date First Issued: | OCT/2008 | Last Reviewed: | 03/06/2021 | | Review Date: | 03/06/2024 | | | |
| Endorsed by: | Medicines and TI | herapeutics Commi | | Date: | 27/07/2021 | | | | |
| NSQHS Standards Applicable: | Std 1: Clinical Governance | | | Std 5: Comprehensive Care | | | | | |
| | Std 2: Partnering with Consumers | | | Std 6: Communicating for Safety | | | | | |
| | Std 3: Preventing and Controlling Healthcare Associated Infection | | | Std 7: Blood Management | | | | | |
| | Std 4: Medication Safety | | | Std 8: Recognising and Responding to Acute Deterioration | | | | | |
| Printed or personally saved electronic copies of this document are considered uncontrolled. | | | | | | | | | |
| Access the current version from WNHS HealthPoint. | | | | | | | | | |

The health impact upon Aboriginal people has been considered, and where relevant incorporated and appropriately addressed in the development of this document (insert ISD Number). (Please refer to the Aboriginal Health Impact Statement and Declaration for Department of Health and Health Service Provider Guidelines – please delete once you have completed this).

This document can be made available in alternative formats on request for a person with a disability.

© Women and Newborn Health Service 2020

Copyright of this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.